AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)

Recruitingn/aAges 18 Years - anyAllTCROSS Co., Ltd.
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

JDEPTH-LM Registry is a prospective, observational, multi-center study designed for the efficacy and safety of Double-effect kissing balloon technique (W-KBT) in left main (LM) bifurcation percutaneous coronary intervention (PCI) using Perfusion balloon (PB) and Drug coated balloon (DCB) in patients with left main coronary artery disease (LMD) with left circumflex artery (LCx) ostium stenosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age โ‰ฅ 18 years 2. Patient with stable coronary artery disease, non-ST-elevation myocardial infarction, or unstable angina 3. Left main disease confirmed by coronary angiography or coronary CT angiography 4. Clinical and anatomical eligibility for PCI as agreed by the local Heart Team 5. Patient with consent prior to undergoing PCI 6. Left main Medina classification (1,1,1), (1,0,1), (0,1,1), (0,0,1) confirmed by coronary angiography 7. De novo target lesion in LMT-LAD amenable for crossover stenting with provisional side-branch approach as determined by PCI operator 8. De novo ostial LCx lesions 9. Lesion indicated in No. 8 with a length of less than 10 mm or a stenosis of less than 70% confirmed by coronary angiography Exclusion Criteria: 1. Inability to provide written informed consent 2. Patient with a history of ST-elevation myocardial infarction within the previous 1 week 3. Patient in a state of cardiogenic shock 4. Patient with a history of coronary artery bypass grafting 5. Patient with malignant tumors or other conditions with a life expectancy of less than one year 6. Patient considered suitable for stent placement in the ostial LCx from a medical perspective 7. Patient considered unsuitable for anti-thrombotic therapy after PCI 8. Other patient whom the investigator deems unsuitable for the safe conduct of LM-PCI, including W-KBT
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

32 sites
Ichinomiya Municipal Hospital
Ichinomiya, Japan
Fujita Health University School of Medicine
Toyoake, Japan
Chiba University Hospital
Chiba, Japan
New Tokyo Hospital
Matsudo, Japan
Tokyo Bay Urayasu Ichikawa Medical Center
Urayasu, Japan
Ehime Prefectural Central Hospital
Matsuyama, Japan
Fukuoka Wajiro Hospital
Fukuoka, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, Japan

โ€ฆand 24 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy